Effect Of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients With Heart Failure With A Reduced Ejection Fraction, With And Without Sacubitril/valsartan
SGLT2 inhibitors reduce serious heart failure events in patients with type 2 diabetes, and one trial with dapagliflozin that enrolled patients with mild heart failure and a reduced ejection fraction has reported benefits in patients without diabetes.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Milton Packer Source Type: research
More News: Cardiology | Dapagliflozin | Diabetes | Diabetes Type 2 | Diovan | Empagliflozin | Endocrinology | Forxiga | Heart | Heart Failure | Jardiance | SGLT2 Inhibitors